D-0924-2023 Class III Terminated
FDA drug recall D-0924-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Jul 5, 2023 and is designated Class III. Reason for recall: Superpotent Drug: Out of Specification (OOS) results observed for unit dose content. The recall status is terminated (terminated Feb 26, 2024). Affected quantity: 20,884 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 26, 2023
- Initiation Date
- Jul 5, 2023
- Termination Date
- Feb 26, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 20,884 cartons
Product description
Loteprednol Etabonate Ophthalmic Suspension, 5 mg/mL (0.5%), packaged as one bottle in a carton in a) 10 mL bottle (NDC# 62756-232-55) and b) 15 mL bottle (NDC # 62756-232-56), Rx only, Distributed by: Sun Pharmaceutical Ind., Inc., NJ 08512, Manufactured by: Sun Pharmaceutical Medicare Ltd., India.
Reason for recall
Superpotent Drug: Out of Specification (OOS) results observed for unit dose content.
Distribution pattern
USA nationwide.
Code information
Lot#: a) BAC0334A, Exp 06/2023; BAC0532A, Exp 11/2023 BAD0407A, Exp 08/2024 BAD0425A, Exp 08/2024; b) BAC0335A, Exp 06/2023, BAC0533A, Exp 10/2023, BAD0148A, Exp 03/2024, BAD0320A, Exp 07/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0924-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026